Star Studies

Help us reshape the treatment
for Alzheimer's disease

Are you or is someone you know diagnosed with Alzheimer’s disease AND is donepezil, rivastigmine or galantamine the current treatment? If yes, we invite you to continue reading.

While there is no known cure for Alzheimer’s, in recent years thanks to clinical trials, advances have been made. But more medicines are needed to provide patients, caregivers and their physicians with treatment choices.

Currently three studies are underway to investigate whether a research drug called idalopirdine, given in addition to the Alzheimer’s medicine, donepezil, rivastigmine or galantamine, improves brain functioning in areas such as memory, thinking and reasoning.

Idalopirdine is being jointly developed by Lundbeck and Otsuka Pharmaceutical. Lundbeck is conducting a series of three clinical research studies for Alzheimer's called the STAR studies.

The aim of the three star studies:

  • Test if a new type of drug works and how safe it is in patients with Alzheimer’s disease.
  • Investigate the safety and effectiveness of the drug idalopirdine at varying doses.

It is important to note that idalopirdine has already been tested in clinical studies with promising results.

Why Clinical Research Depends on People like You

Without the valuable participation of people like you, clinical research for Alzheimer's treatments cannot be developed. We appreciate you taking the time to consider whether participation in an Alzheimer's clinical research study might be an option for you or the person you know with Alzheimer's.

By taking part in this clinical research study, you and others like you will be helping to evaluate an investigational drug to determine its safety and effectiveness for Alzheimer’s patients with mild to moderate symptoms when used with another Alzheimer's medicine.